Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
C. Valsuani
Observed names:
Chiara Valsuani,
VALSUANI, CHIARA,
Valsuani Chiara,
Valsuani, Chiara
Institution:
Azienda USL Toscana Nord Ovest
Observed institutions:
University of Pisa,
Ospedale degli Infermi,
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo,
Ospedale Versilia,
Istituti Ospitalieri di Cremona,
Azienda USL Toscana Nord Ovest
show all 6
OpenAlex ID:
A5056207263
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
2013
·
Alfredo Falcone
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
85
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
2015
·
Andrea Camerini
, Cheti Puccetti
, et al.
·
BMC Cancer
·
80
PDF
Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
2018
·
Daniele Campa
, Martina Matarazzi
, et al.
·
International Journal of Cancer
·
61
PDF
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.
2013
·
Fotios Loupakis
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
40
Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma
2007
·
A. Sgambato
, A. Camerini
, et al.
·
Cancer Biology & Therapy
·
38
PDF
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
2017
·
on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest
, Chiara Cremolini
, et al.
·
BMC Cancer
·
33
PDF
Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status
2009
·
A. Camerini
, C. Valsuani
, et al.
·
Annals of Oncology
·
31
PDF
A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO)
2012
·
G. Masi
, F. Loupakis
, et al.
·
Annals of Oncology
·
28
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO).
2013
·
Gianluca Masi
, Fotios Loupakis
, et al.
·
Journal of Clinical Oncology
·
23
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
2011
·
Andrea Camerini
, Sara Donati
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
18
PDF
Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
2017
·
Daniele Campa
, Manuela Pastore
, et al.
·
International Journal of Cancer
·
17
PDF
Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.
2014
·
Fotios Loupakis
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
17
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO).
2012
·
Lisa Salvatore
, Gianluca Masi
, et al.
·
Tumori
·
11
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
2014
·
Chiara Cremolini
, Fotios Loupakis
, et al.
·
Journal of Clinical Oncology
·
7
Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
2014
·
C. Cremolini
, F. Loupakis
, et al.
·
Annals of Oncology
·
4
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
2009
·
Chiara Valsuani
, Olimpia Siclari
, et al.
·
Cases Journal
·
4
PDF
Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono
2013
·
Lisa Salvatore
, Gianluca Masi
, et al.
·
Annals of Oncology
·
3
PDF
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients
2009
·
Andrea Camerini
, Marianna Rondini
, et al.
·
Cancer Biology & Therapy
·
3
PDF
Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial)
2009
·
D. Amoroso
, S. Donati
, et al.
·
Journal of Clinical Oncology
·
2
Phase Ii Trial of Metronomic Oral Vinorelbine As First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer (Move Trial)
2014
·
A. Camerini
, C. Puccetti
, et al.
·
Annals of Oncology
·
1
PDF
Effect of fulvestrant treatment on serum VEGF levels in hormone-sensitive metastatic breast cancer patients
2009
·
A. Camerini
, O. Garrone
, et al.
·
Journal of Clinical Oncology
·
1
Mixed endometrial carcinoma: is it time to profile the two components separately?
2026
·
Gianna Musettini
, Paola Pretelli
, et al.
·
Frontiers in Oncology
PDF
Cancer as family disease
2017
·
L. Bertagnini
, P. Pacetti
, et al.
·
Annals of Oncology
PDF
Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using 18fluorine-2-deoxy-d-glucose positron emission tomography-computed tomography: a prospective study
2016
·
A. Del Freo
, R. Della Seta
, et al.
·
Annals of Oncology
Gemcitabine-Capecitabine Chemotherapy Plus Intra- Arterial Epirubicin-Cisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy: A Retrospective Analysis
2016
·
Ginocchi Laura
, Valsuani Chiara
, et al.
·
Journal of Cancer Sciences
PDF
Show more works
View as search
Works count:
37
Citation count:
507
H-index:
12
I10-index:
13
Year
Topic
Type